Literature DB >> 21632145

Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis.

Ioannis Gioulbasanis1, Panagiotis Georgoulias, Panagiotis J Vlachostergios, Vickie Baracos, Sunita Ghosh, Zoe Giannousi, Christos N Papandreou, Dimitris Mavroudis, Vassilis Georgoulias.   

Abstract

PURPOSE: Lung cancer patients frequently present with weight loss in the context of the cachexia syndrome. Despite its high clinical significance, definite diagnostic criteria of cachexia are lacking. Nutritional screening questionnaires, like the Mini Nutritional Assessment (MNA), have been proposed for the timely diagnosis of the syndrome. The aim of this study was to evaluate the correlation of MNA with laboratory markers of inflammation/cachexia in patients with metastatic lung cancer. The prognostic value of the measured parameters was also examined. PATIENTS AND METHODS: Patients with metastatic lung cancer referred for systemic therapy were eligible. Baseline clinical characteristics were recorded and nutritional status was assessed using MNA. Blood samples were also collected and the following parameters were measured: hemoglobin (Hb), albumin (Alb), C-reactive protein (CRP), ghrelin, adiponectin, leptin and insulin growth factor I (IGF-I).
RESULTS: Totally, 115 patients (101 males) [median age 66 years (range 32-86)] were evaluated. According to MNA score, 27 (23.5%) patients were well nourished, 59 (51.3%) were at nutritional risk and 29 (25.2%) were already malnourished at diagnosis. MNA correlated with the following parameters: Hb (p=0.001), albumin (p<0.001), CRP (p=0.002), adiponectin (p=0.037) and leptin (p=0.008). After a median follow up of 38.2 months, multivariate analysis revealed that age (p=0.008), number of metastatic sites (p<0.001), MNA (p=0.044) and leptin (p=0.004) independently correlated with overall survival.
CONCLUSIONS: Based on the MNA, the majority of patients were either malnourished or at nutritional risk. MNA correlated with laboratory parameters related to inflammation/cachexia and was independently associated with survival.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632145     DOI: 10.1016/j.lungcan.2011.05.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  25 in total

1.  Frailty and Brain-Muscle Correlates in Older People With Type 2 Diabetes: A structural-MRI Explorative Study.

Authors:  I Bourdel-Marchasson; G Catheline; S Regueme; M Danet-Lamasou; E Barse; F Ratsimbazafy; L Rodriguez-Manas; K Hood; A J Sinclair
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

Review 2.  The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer.

Authors:  John White
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Novel simple and practical nutritional screening tool for cancer inpatients: a pilot study.

Authors:  Jamal Zekri; Julie Morganti; Azhar Rizvi; Bakr Bin Sadiq; Ian Kerr; Mohamed Aslam
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

4.  Nutritional assessment with different tools in leukemia patients after hematopoietic stem cell transplantation.

Authors:  Boshi Wang; Xia Yan; Jingjing Cai; Yu Wang; Peng Liu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

5.  Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.

Authors:  P J Vlachostergios; I Gioulbasanis; S Ghosh; C Tsatsanis; G Papatsibas; A Xyrafas; E Hatzidaki; C Vasiliou; K Kamposioras; S Agelaki; A N Margioris; D Nasi; V Georgoulias; C N Papandreou
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

6.  Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial.

Authors:  Isabelle Bourdel-Marchasson; Christelle Blanc-Bisson; Adélaïde Doussau; Christine Germain; Jean-Frédéric Blanc; Jérôme Dauba; Cyril Lahmar; Eric Terrebonne; Cédric Lecaille; Joël Ceccaldi; Laurent Cany; Sandrine Lavau-Denes; Nadine Houede; François Chomy; Jessica Durrieu; Pierre Soubeyran; Pierre Senesse; Geneviève Chene; Mariane Fonck
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

7.  The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.

Authors:  Paraskevi Boura; Dimitra Grapsa; Stylianos Loukides; Maria Angelidou; Konstantina Tsakanika; Nikolaos Syrigos; Ioannis Gkiozos
Journal:  Lung Cancer Manag       Date:  2017-11-17

8.  Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer.

Authors:  Yusuke Yonenaga; Tateaki Naito; Taro Okayama; Midori Kitagawa; Noriko Mitsuhashi; Takeshi Ishii; Hiroshi Fuseya; Toshimi Inano; Ayumu Morikawa; Miwa Sugiyama; Keita Mori; Akifumi Notsu; Takanori Kawabata; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Akira Tanuma; Toshiaki Takahashi
Journal:  J Multidiscip Healthc       Date:  2021-06-21

9.  Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients.

Authors:  Anthony M Villani; Michelle D Miller; Ian D Cameron; Susan Kurrle; Craig Whitehead; Maria Crotty
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-05-18       Impact factor: 12.910

10.  Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.

Authors:  Katsutoshi Ando; Fumiyuki Takahashi; Motoyasu Kato; Norihiro Kaneko; Tokuhide Doi; Yuichiro Ohe; Fumiaki Koizumi; Kazuto Nishio; Kazuhisa Takahashi
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.